Tolerability and efficacy of the monoaminergic stabilizer (-)-OSU6162 (PNU-96391A) in Huntington's disease: A double-blind cross-over study

Acta Neuropsychiatrica

Volumn 26, Issue 5, 2013, Pages 298-306

  Kloberg, Angelica ^a   Constantinescu, Radu ^b   Nilsson, Marie Karin Lena ^c   Carlsson, Maria Lizzie ^c   Carlsson, Arvid ^c   Wahlström, Jan ^c   Haghighi, Sara ^b  

^a Carlsson Research AB   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

depression; huntington's disease; monoaminergic stabilizer; vitality

Indexed keywords

3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; PIPERIDINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; MENTAL FUNCTION; MOOD; MOTOR PERFORMANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SHORT FORM 36; SOCIAL STATUS; SYMPTOMATOLOGY; DRUG EFFECTS; HEALTH STATUS; HUNTINGTON DISEASE; MIDDLE AGED; MOTOR ACTIVITY; QUESTIONNAIRE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HEALTH STATUS; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; MOTOR ACTIVITY; PIPERIDINES; QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84911420581     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1017/neu.2014.16     Document Type: Article

References (28)

1. PETERSN A, BJRKQVIST M. Hypothalamic-edocrine aspects in Huntingtons disease. Euro J Neurosci 2006;24:961-967
2. WALKER FO. Huntingtons disease. Lancet 2007;369:218-228
3. PALEACU D. Tetrabenazine in the treatment of Huntingtons disease. Neuropsychiatr Dis Treat 2007;3:545-551
4. RUNG JP, RUNG E, HELGESON L et al. Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization. J Neural Trasm 2008;115:899-908
5. CARLSSON ML, BURSTEIN ES, KLOBERG A et al. I. In vivo evidence for partial agonist effects of (-)-OSU6162 and ( + )-OSU6162 on 5-HT2A serotonin receptors. J Neural Trasm 2011;118:1511-1522
6. BURSTEIN ES, CARLSSON ML, OWENS M et al. II. In vitro evidence that (-)-OSU6162 and ( + )-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors. J Neural Transm 2011;118:1523-1533
7. TEDROFF J, EKESBO A, SONESSON C, WATERS N, CARLSSON A. Long-lasting improvement following (-)-OSU6162 in a patient with Huntingtons disease. Neurology 1999;53: 1605-1606
8. DE YEBENES JG, LANDWEHRMEYER B, SQUITIERI F et al. Pridopidine for the treatment of motor function in patients with Huntingtons disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2011;10:1049-1057
9. THE HUNTINGTON STUDY GROUP HART INVESTIGATORS. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntingtons disease. Mov Disord 2013;28:1407-1415
10. LANDWEHRMEYER GB, MARDER K, BIILMANN-RONN B et al. Effects of the dopaminergic stabilizer pridopidine on motor symptoms in Huntingtons disease: a meta-analysis. Clin Genet 2011;80(Suppl. 1):48. (Abstract)
11. EUROPEAN HUNTINGTONS DISEASE NETWORK: www.euro-hd. net
12. SHOULSON I, KURLAN R, RUBIN A. Assessment of functional capacity in neurodegenerative movement disorders: Huntingtons disease as a prototype. In: Munsat T, editor. Quantification of Neurologic Deficit. Stoneham, MA: Butterworths, 1989. p. 271-283
13. SONESSON C, LIN CH, HANSSON L et al. Substituted (S)- phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structureactivity relationships. J Med Chem 1994;37:2735-2753
14. HUNTINGTON STUDY GROUP. Unified Huntingtons Disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-142
15. WARE JE, SNOW KK, KOSINSKI M et al. SF-36 Health Survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Centre, 1993
16. Website: www.alswh.org.au, ALSWH (Australian Longitudinal Study on Womens Health). Additional site information: For Researchers/Data/Data Dictionary Supplement/ Section 2, Core Survey Dataset/ 2.3 Healthrelated Quality of Life Variables, SF-36 (http://www.alswh. org.au/for-researchers/data/data-dictionary-supplement)
17. ALTMAN DG. Practical Statistics for Medical Research, 1st edn. London: Chapman and Hall, 1991
18. HODGES JL JR, LEHMANN EL. Hodges-Lehmann estimators. In: Kotz S, Johnson NL, READ CB, editors. Encyclopedia of Statistical Sciences, Volume 3. New York: John Wiley &Sons, 1983. p. 463-465
19. HOLLANDER M, WOLFE DA. Nonparametric Statistical Methods, 2nd edn. New York: John Wiley &Sons, 1999
20. SUCHMAN AL, ADER R. Pharmacodynamics and drug action. Classic conditioning and placebo effects in crossover studies. Clin Pharmacol Ther 1992;52:372-377
21. FARIA V, FREDRIKSON M, FURUMARK T. Imaging the placebo response: a neurofunctional review. Eur Neuropsychopharmacol 2008;18:473-485
22. ELBOURNE DR, ALTMAN DG, HIGGINS JPT et al. Metaanalyses involving cross-over trials: methodological issues. Int J Epidemiol 2002;31:140-149
23. JOHANSSON B, CARLSSON A, CARLSSON ML et al. Placebocontrolled cross-over study of the monoaminergic stabiliser (-)-OSU6162 in mental fatigue following stroke or traumatic brain injury. Acta Neuropsychiatrica 2012;24:266-274
24. SVENSSON KA, FALCONE JF, JOHANSSON AM et al. The actions of the dopamine stabilizer ACR16, but not (-)-OSU6162, in behavioral and neurochemical assays are not dependent on the presence of functional D2 receptors. Society for Neuroscience Annual Meeting, 9-13 November 2009, San Diego
25. NATESAN S, SVENSSON KA, RECKLESS GE et al. The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propylpiperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)- 1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J Pharmacol Exp Ther 2006;318:810-818
26. TOLBOOM N, BERENDSE HW, LEYSEN JE et al. The dopamine stabilizer (-)-OSU6162 occupies a subpopulation of striatal dopamine D2/D3 receptors: an [11C]-raclopride PET study in healthy human subjects. 2014. Submitted to Neuropsychopharmacology, minor revision
27. RODRIGUEZ CA, AZIE NE, ADAMS G et al. Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers. J Clin Pharmacol 2004;44:276-283
28. RUIZ C, CASAREJOS MJ, RUBIO I et al. The dopaminergic stabilizer, (-)-OSU6162, rescues striatal neurons with normal and expanded polyglutamine chains in huntingtin protein from exposure to free radicals and mitochondrial toxins. Brain Res 2012;1459:100-112.